AgeX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $345 | $645 |
| Accounts and grants receivable, net | 57 | 4 |
| Prepaid expenses and other current assets | 352 | 1,804 |
| Total current assets | 754 | 2,453 |
| Restricted cash | 50 | 50 |
| Intangible assets, net | 607 | 738 |
| Convertible note receivable | 10,554 | - |
| TOTAL ASSETS | $11,965 | $3,241 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY/(DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $2,176 | $1,034 |
| Loans due to Juvenescence, net of debt issuance costs, current portion | 3,672 | 7,646 |
| Related party payables, net | 66 | 141 |
| Warrant liability | - | 180 |
| Insurance premium liability and other current liabilities | - | 1,077 |
| Total current liabilities | 5,914 | 10,078 |
| Loans due to Juvenescence, net of debt issuance costs, net of current portion | 693 | 10,478 |
| TOTAL LIABILITIES | 6,607 | 20,556 |
| Commitments and contingencies (Note 10) | - | - |
| Stockholders’ equity/(deficit): | ||
| Preferred stock, $0.0001 par value, 5,000 shares authorized: | - | - |
| Series A preferred stock; no par value; stated value $100 per share; 212 and nil shares issued and outstanding, respectively | - | - |
| Series B preferred stock; no par value; stated value $100 per share; 148 and nil shares issued and outstanding, respectively | - | - |
| Common stock, $0.0001 par value, 200,000 shares authorized, 1,079 shares issued and outstanding | - | - |
| Additional paid-in capital | 136,482 | 98,998 |
| Accumulated deficit | (131,013) | (116,210) |
| Total AgeX Therapeutics, Inc. stockholders’ equity/(deficit) | 5,469 | (17,212) |
| Noncontrolling interest | (111) | (103) |
| Total stockholders’ equity/(deficit) | 5,358 | (17,315) |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY/(DEFICIT) | $11,965 | $3,241 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.